|Chemical and physical data|
|Molar mass||144083.69 g·mol−1|
Common side effects include pain or redness at the site of injection. Other side effects may include hypersensitivity reactions. It is directed against calcitonin-related polypeptides alpha and beta.
This drug was developed by Eli Lilly. It was approved for medical use in the United States in 2018, becoming the third CGRP inhibitor to do so. When used for migraines it costs about 7,000 USD per year in the United States as of 2019.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|